Effects of oral propranolol for circumscribed choroidal hemangioma

ABSTRACT Purpose: We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma. Methods: In this prospective, longitudinal interventional study, we administered oral propranolol at a dosage of 1.5 mg/kg/day to five patients with circumscribed choroidal hemangioma. We then evaluated visual acuity, binocular indirect ophthalmoscopy, optical coherence tomography, optical coherence tomography angiography, fluorescein and indocyanine green angiography, and ocular ultrasonography at regular intervals and compared changes from the baseline assessments. Results: No clinical or diagnostic changes were observed in the sizes of the circumscribed choroidal hemangiomas during treatment. Complications due to the hemangioma were reduced in the first four months of treatment, followed by maintenance, before worsening in the subsequent three months. Conclusions: The study showed that oral propranolol at a dose of 1.5 mg/kg/day did not offer effective monotherapy in the treatment of circumscribed choroidal hemangioma.

摘要 研究目的：本研究旨在评估口服普萘洛尔（oral propranolol）治疗局限性脉络膜血管瘤的效果。方法：本研究为前瞻性纵向干预性研究，纳入5名局限性脉络膜血管瘤患者，给予剂量为1.5 mg/kg/天的口服普萘洛尔治疗。随后我们定期对受试者开展视力检查、双目间接检眼镜检查、光学相干断层扫描（optical coherence tomography）、光学相干断层扫描血管造影（optical coherence tomography angiography）、荧光素血管造影与吲哚菁绿血管造影及眼部超声检查，并将各项检查结果与基线评估值进行对比，分析其变化情况。结果：治疗期间，局限性脉络膜血管瘤的病灶大小未出现临床或影像学层面的显著变化。治疗前4个月内，血管瘤相关并发症有所减轻，随后进入维持阶段，后续3个月并发症再次加重。结论：本研究证实，剂量为1.5 mg/kg/天的口服普萘洛尔单药治疗，无法为局限性脉络膜血管瘤提供有效的单一疗法。